FOR RESEARCH USE ONLY
Early human researchLongevity research

NAD+

Nicotinamide Adenine Dinucleotide researched for cellular energy, sirtuin activity and longevity protocols.

01Redox biology02Sirtuins & PARPs03Cellular energetics
Molecular signature / nad-plus
Structural identity

Cellular redox coenzyme rather than a classical amino-acid-chain compound

Also known as

Nicotinamide adenine dinucleotide · Oxidised nicotinamide adenine dinucleotide

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

NAD+ (Nicotinamide Adenine Dinucleotide) is a fundamental coenzyme present in every cell, central to redox reactions, mitochondrial energy production, DNA repair and sirtuin-mediated longevity signalling. Cellular NAD+ levels decline substantially with age, and direct replenishment is a leading geroscience research target.

The research question

NAD+ is central to electron transfer and acts as a substrate for sirtuins, PARPs and CD38. Research must distinguish a short-term rise in measured NAD+ from durable changes in mitochondrial function, DNA repair or health outcomes.

Section 02

Mechanism & research themes

Serves as a substrate for sirtuins (SIRT1–7), PARP DNA-repair enzymes and CD38, while functioning as an electron carrier in oxidative phosphorylation. Restoration of NAD+ levels reactivates downstream longevity, repair and metabolic pathways.

01

Restoration of age-associated NAD+ decline

02

Activation of sirtuin-mediated longevity and metabolic pathways

03

Enhanced mitochondrial function and cellular energy output

04

Support for DNA repair via PARP enzyme substrate availability

05

Cognitive clarity and energy improvements reported anecdotally

06

Emerging research in neurodegeneration and metabolic disease

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Early human research

NAD+ biochemistry is established, but route-specific replenishment and long-term functional outcomes are separate questions. Intravenous, injectable and oral precursor evidence should not be merged.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 50–250mg subcutaneously or intramuscularly per session, 2–5× weekly. Higher-dose IV protocols (500–1000mg) are used in clinical research over 60–120 minute infusions. Start low — flushing and GI effects are dose-dependent.

Reported persistence

Plasma half-life is short (minutes), but intracellular NAD+ pool replenishment persists for days.

Calculator starting point

100 mg per reference dose

5 doses per week · 4-week cycle

3 mL default reconstitution volume

50–300 mg SC daily/most days, short 2–6 week cycles.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate NAD+
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 500mg vial with 5–10mL bacteriostatic water for 50–100mg/mL. Reconstitute slowly down the side of the vial; the solution may appear faintly yellow.

Storage reference

Lyophilised: 2–8°C, stable 12–18 months; avoid freeze-thaw. Reconstituted: 2–8°C, protect from light, use within 14–21 days due to NAD+ instability in solution.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

SC/IM injections can sting significantly — slow administration and lower concentrations help.

L2

Rapid infusion is associated with flushing, nausea, chest pressure and anxiety — titrate carefully.

L3

Reconstituted NAD+ is less stable than peptides; use within 2–3 weeks.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only